Jefferies Financial Group Inc. Sells 8,157,091 Shares of Taysha Gene Therapies, Inc. $TSHA

Jefferies Financial Group Inc. decreased its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 79.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,156,642 shares of the company’s stock after selling 8,157,091 shares during the quarter. Jefferies Financial Group Inc. owned approximately 0.79% of Taysha Gene Therapies worth $7,052,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC raised its position in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after purchasing an additional 4,697,611 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Taysha Gene Therapies during the 3rd quarter worth about $1,126,000. Rafferty Asset Management LLC grew its position in shares of Taysha Gene Therapies by 102.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 239,785 shares of the company’s stock valued at $784,000 after buying an additional 121,102 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Taysha Gene Therapies in the third quarter valued at about $53,000. Finally, Xponance Inc. increased its stake in shares of Taysha Gene Therapies by 29.1% in the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock valued at $54,000 after buying an additional 3,738 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Up 0.4%

Shares of NASDAQ:TSHA opened at $4.59 on Tuesday. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $6.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The business’s 50-day moving average is $4.77 and its 200-day moving average is $4.47. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -13.91 and a beta of 1.02.

Insiders Place Their Bets

In other Taysha Gene Therapies news, CFO Kamran Alam sold 23,849 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $109,943.89. Following the transaction, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sean P. Nolan sold 41,312 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer owned 2,908,257 shares in the company, valued at $13,407,064.77. The trade was a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on TSHA shares. UBS Group set a $11.00 price objective on Taysha Gene Therapies in a research note on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a report on Friday, November 14th. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, Wells Fargo & Company upped their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.91.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.